Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback